Desager et al., 1982 - Google Patents
Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failureDesager et al., 1982
- Document ID
- 4259849863650801590
- Author
- Desager J
- Costermans J
- Verberckmoes R
- Harvengt C
- Publication year
- Publication venue
- Nephron
External Links
Snippet
The influence of hemodialysis on plasma fenofibric acid kinetics has been investigated in patients with chronic renal failure given 300 mg of fenofibrate in a single oral dose. A very pronounced lengthening of the fenofibric acid plasma decay was observed in both …
- 210000002381 Plasma 0 title abstract description 36
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/824—Arteriosclerosis
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Du Vivier et al. | Treatment of psoriasis with azathioprine | |
| Jadoul et al. | Influence of hemodialysis membrane type on pentosidine plasma level, a marker of “carbonyl stress” | |
| Jeppesen et al. | Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients. A randomized, double-blind, crossover, placebo-controlled study | |
| Illingworth et al. | The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia | |
| Desager et al. | Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure | |
| Gisclon et al. | The effect of probenecid on the renal elimination of cimetidine | |
| Miller et al. | Controlled clinical trial of a new bile acid‐sequestering resin, colestipol, in the treatment of hypercholesterolemia | |
| Uribe et al. | Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy: a double-blind randomized controlled study | |
| Christensen et al. | Treatment with disulfiram in chronic nickel hand dermatitis | |
| Mahon et al. | Studies on the absorption and distribution of doxycycline in normal patients and in patients with severely impaired renal function | |
| Hoeg et al. | Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin. | |
| Schröder et al. | Treatment of hyperhomocysteinemia in children on dialysis by folic acid | |
| Chan et al. | Response patterns to DL-carnitine in patients on maintenance haemodialysis | |
| Grob et al. | Dermatomyositis-like syndrome induced by nonsteroidal anti-inflammatory agents | |
| Sirtori et al. | Clinical evaluation of MK‐185: A new hypolipidemic drug | |
| Ma et al. | Long‐term treatment of portal‐systemic encephalopathy with lactulose | |
| Abrahamsson et al. | Effect of Short-Term Treatment with Pivalic Acid Containing Antibiotics on Serum Carnitine Concentration-A Risk Irrespective of Age | |
| Wanner et al. | Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients | |
| Dux et al. | Anaphylactic shock induced by diclofenac | |
| Mohamed et al. | Effects of gender and race on albuterol pharmacokinetics | |
| Davies et al. | The effect of ageing on the pharmacokinetics of dihydrocodeine | |
| Wojcicki et al. | Clinical evaluation of cerniton as lipid lowering agent | |
| Vester et al. | Long‐term monitoring during clofibrate therapy | |
| Harvengt et al. | Colestipol in familial type II hyperlipoproteinemia: A three‐year trial | |
| Marbury et al. | Hemodialysis of acetaminophen in uremic patients |